Mayo v. Prometheus: Implications for Patents, Biotechnology, and Personalized Medicine
The recent enactment of the Leahy-Smith America Invents Act (AIA), P.L. 112-29, suggests congressional interest in patents on diagnostic methods. In particular, Section 27 of the AIA required the U.S. Patent and Trademark Office to conduct a study on the patenting of genetic diagnostic tests. The 2012 decision of the Supreme Court in Mayo Collaborative Services v. Prometheus Laboratories, Inc. also addressed these sorts of patents. The Court's decision arguably placed severe limitations on the ability of inventors to obtain diagnostic method patents.
THE DOCUMENT INCLUDES FOLLOWING FILES:
|#||FILE NAME||Document Date||Order ID:||Number of Pages||PRICE|
|1||R42815.pdf||Nov 06, 2012||R42815||13||$19.95||ADD TO CART|